|
|
|
|
| LEADER |
03293nam a22002895i 4500 |
| 001 |
000278418 |
| 005 |
20200922132704.0 |
| 007 |
cr nn 008mamaa |
| 008 |
180306s2018 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9781493977048
|
| 024 |
7 |
|
|a 10.1007/978-1-4939-7704-8
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Biomarkers for Alzheimer’s Disease Drug Development /
|c edited by Robert Perneczky.
|
| 250 |
|
|
|a 1st ed. 2018.
|
| 260 |
# |
# |
|a New York, NY :
|b Springer New York :
|b Imprint: Humana,
|c 2018.
|
| 300 |
|
|
|a XV, 372 p. 54 illus., 45 illus. in color. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Methods in Molecular Biology,
|v 1750
|
| 505 |
0 |
|
|a Epidemiology of Dementia: The Burden on Society, the Challenges for Research -- Population-based Approaches to Alzheimer’s Disease Prevention -- Systems Biology Methods for Alzheimer’s Disease Research towards Molecular Signatures, Subtypes and Stages and Precision Medicine. Application in Cohort Studies and Trials -- CSF Lipidomics Analysis: High-Resolution Mass Spectrometry Analytical Platform -- CSF N-glycomics using MALDI MS Techniques in Alzheimer’s Disease -- MicroRNA Profiling of Alzheimer’s Disease Cerebrospinal Fluid -- Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-β in Human Blood Plasma -- Mass Spectrometry-based Metabolomic Multiplatform for Alzheimer’s Disease Research -- Blood-based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis within the Dimensional Spectrum of Neurodegenerative Diseases -- Functional Magnetic Resonance Imaging in Alzheimer’ Disease Drug Development -- Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies -- Hybrid PET-MRI in Alzheimer’s Disease Research -- Amyloid PET Imaging: Standardization and Integration with Other Alzheimer Disease Biomarkers -- The use of 18F-FDG PET in the Diagnostic Workup of Alzheimer’s Dementia -- Quantification of Tau Load in Alzheimer’s Disease Clinical Trials Using Positron Emission Tomography -- Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach -- Unbiased Lipidomics and Metabolomics of Human Brain Samples -- Neuropathological Assessment as an Endpoint in Clinical Trial Design -- Analysis of micro-RNA Expression by qPCR on a Microfluidics Platform for Alzheimer’s Disease Biomarker Discovery -- Telomere length shortening in Alzheimer’s disease – procedures for a causal investigation using single nucleotide polymorphisms in a Mendelian Randomization study -- Quantifying miRNA Deregulation in Alzheimer’s Disease -- Imaging of Microglial Activation in Alzheimer’s Disease by [11C]PBR28 PET -- In Vivo Two-photon Calcium Imaging of Hippocampal Neurons in Alzheimer Mouse Models -- Cognitive Assessment in Alzheimer’s Disease Clinical Trials -- Data Mining and Machine Learning Methods for Dementia Research. .
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
| 700 |
1 |
|
|a Perneczky, Robert.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 900 |
|
|
|a Libro descargado a ALEPH en bloque (proveniente de proveedor)
|